Slingshot members are tracking this event:

Novartis (NVS) agrees to license to PureTech Health two mTORC1 inhibitors in studying age-related focuses. New ew subsidiary called resTORbio will head developments of these candidates.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 24, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Restorbio, License, Mtorc1 Inhibitors